PROVEN INHALED PAH EFFICACY
The only inhaled PAH (WHO Group 1) therapy to demonstrate significant clinical improvement through a combined endpoint at week 121
Learn More
 
PRECISION DOSING
Learn about how the I-neb® Adaptive Aerosol Delivery (AAD®) system delivers precise dosing of VENTAVIS2,3
Learn More
Faster Treatments*
Higher 20 mcg/mL concentration shortens treatment times for patients who have repeatedly experienced extended treatment times on the
5-mcg dose*†
Learn More

*The VENTAVIS 20-mcg/mL concentration is intended for patients who are maintained at the 5-mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. VENTAVIS 10-mcg/mL ampules are still available. VENTAVIS should be taken 6 to 9 times daily, at least 2 hours apart.

†Based on an in vitro study with a manually generated 28.3-L/min, 15-sec inhalation cycle breathing pattern.14

INDICATION

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.

Pulmonary Venous Hypertension

  • Stop VENTAVIS immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Bronchospasm

  • VENTAVIS inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.

ADVERSE REACTIONS

Serious Adverse Events

Adverse Events

DRUG INTERACTIONS

Antihypertensives and Vasodilators

Anticoagulants and Platelet Inhibitors

SPECIFIC POPULATIONS

Lactation

Please see full Prescribing Information.

cp-134777

*The VENTAVIS 20 mcg/mL concentration order form is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. VENTAVIS 10 mcg/mL ampules are still available. VENTAVIS should be taken 6 to 9 times daily, at least 2 hours apart.

For more information about VENTAVIS, please call 1-800-Janssen (1-800-526-7736).

OPEN CLOSE EXPAND

INDICATION

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.

Pulmonary Venous Hypertension

  • Stop VENTAVIS immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

Bronchospasm

  • VENTAVIS inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.

ADVERSE REACTIONS

Serious Adverse Events

  • Serious adverse events reported include congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure.

Adverse Events

  • Adverse events reported in a Phase 3 clinical trial occurring with a ≥3% difference between VENTAVIS patients and placebo patients were vasodilation (flushing) (27% vs 9%), increased cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), insomnia (8% vs 2%), nausea (13% vs 8%), hypotension (11% vs 6%), vomiting (7% vs 2%), alkaline phosphatase increased (6% vs 1%), flu syndrome (14% vs 10%), back pain (7% vs 3%), tongue pain (4% vs 0%), palpitations (7% vs 4%), syncope (8% vs 5%), GGT increased (6% vs 3%), muscle cramps (6% vs 3%), hemoptysis (5% vs 2%), and pneumonia (4% vs 1%).

DRUG INTERACTIONS

Antihypertensives and Vasodilators

  • VENTAVIS has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.

Anticoagulants and Platelet Inhibitors

  • VENTAVIS also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants or platelet inhibitors.

SPECIFIC POPULATIONS

Lactation

  • Advise not to breastfeed during treatment with VENTAVIS.

Please see full Prescribing Information.

cp-134777